Vicuron Pharmaceuticals Promotes David S. Krause, M.D., to Executive Vice President and Chief Medical Officer
January 24 2005 - 1:00AM
PR Newswire (US)
Vicuron Pharmaceuticals Promotes David S. Krause, M.D., to
Executive Vice President and Chief Medical Officer KING OF PRUSSIA,
Penn., Jan. 24 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals
Inc. (Nasdaq: MICU; Nuovo Mercato) announced today that it has
promoted David S. Krause, M.D. to the position of Executive Vice
President and Chief Medical Officer. He will replace Timothy J.
Henkel, M.D., Ph.D., who is leaving the company to pursue other
opportunities. "David has played a pivotal role in developing our
two lead product candidates, dalbavancin and anidulafungin," said
George F. Horner, III, Vicuron's President and Chief Executive
Officer. "His leadership strength and proven track record will
serve us well as we move through the final phase of clinical
coordination in the regulatory process necessary to bring these two
products to market." Since joining Vicuron in 2002, Dr. Krause has
been serving as Senior Vice President of Clinical Research and
Medical Affairs and, in that role, has been largely responsible for
the execution of all of the company's clinical trial programs to
date. Prior to joining Vicuron, he worked for more than a decade in
various clinical and medical affairs positions at GlaxoSmithKline
(GSK) focused mostly on the company's pediatric and adult vaccine
programs. During his tenure, Dr. Krause played an integral role in
successfully bringing a number of infectious disease products to
the market, including Engerix-B(R), Havrix(R), Twinrix(R) and
Infanrix(R), all of which became leading products for the
prevention of hepatitis B, A, and childhood pertussis. Dr. Krause
received his M.D. degree from Temple University School of Medicine
and his B.A. degree from The Pennsylvania State University. He
completed his residency in internal medicine at Temple University
Hospital in 1980, and is a Fellow of the American College of
Physicians. Prior to joining industry at SmithKline Beecham in
1990, Dr. Krause practiced internal medicine for 10 years in the
Philadelphia area. He also served as Adjunct Assistant Professor of
Medicine at Temple University Hospital from 1990 - 2000 and
Clinical Assistant Professor of Medicine at the Medical College of
Pennsylvania from 1992 - 1994. His work has been published and
presented in numerous infectious disease journals and at scientific
conferences worldwide. About Vicuron Pharmaceuticals Vicuron
Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing, manufacturing and commercializing vital
medicine for seriously ill patients. The company has two New Drug
Applications pending with the U.S. Food and Drug Administration for
its lead products, dalbavancin, a novel intravenous antibiotic for
the treatment of serious Gram-positive infections, and
anidulafungin, a novel antifungal agent. Vicuron's versatile
research engine integrates industry-leading expertise in functional
genomics, natural products discovery, mechanism-based drug design
and combinatorial and medicinal chemistry. These approaches are
yielding promising novel and next-generation compounds, many of
which are in the later stages of preclinical development. In
addition, the company has research and development collaborations
with leading pharmaceutical companies, such as Novartis and Pfizer.
Forward-Looking Statements This news release contains
forward-looking statements that predict or describe future events
or trends. The matters described in these forward- looking
statements are subject to known and unknown risks, uncertainties
and other unpredictable factors, many of which are beyond Vicuron's
control. Vicuron faces many risks that could cause its actual
performance to differ materially from the results predicted by its
forward-looking statements, including the possibilities that
clinical trials and the results thereof might be delayed or
unsuccessful, that the timing of the filing of any new drug
application or any amendment to a new drug application might be
delayed, that clinical trials might indicate that a product
candidate is unsafe or ineffective, that the FDA might require
additional information to be submitted and additional actions to be
taken before it will make any decision, that any filed new drug
application may not be approved by the FDA, that ongoing
proprietary and collaborative research might not occur or yield
useful results, that the pipeline may not yield a new clinical
candidate or a commercial product, that a third party may not be
willing to license Vicuron's product candidates on terms acceptable
to it or at all, that competitors might develop superior
substitutes for Vicuron's products or market these competitive
products more effectively, that a sales force may not be developed
as contemplated and that one or more of Vicuron's product
candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission
contain a fuller description of these and many other risks to which
Vicuron is subject. Because of those risks, Vicuron's actual
results, performance or achievements may differ materially from the
results, performance or achievements contemplated by its
forward-looking statement. The information set forth in this news
release represents management's current expectations and
intentions. Vicuron assumes no responsibility to issue updates to
the forward-looking matters discussed in this news release.
DATASOURCE: Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein,
M.D. of Vicuron Pharmaceuticals Inc., +1-610-205-2312, or ; or E.
Blair Schoeb of WeissComm Partners, +1-212-923-6737, or ; or Aline
Schimmel of Burns McClellan, +1-212-213-0006, or , both for Vicuron
Pharmaceuticals Inc. Web site: http://www.vicuron.com/
Copyright